🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Non-Small Cell Lung Cancer With EGFR Mutation

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site📍 Shanghai Fudan University · Tests: ORIENT-31 regimen, SBRT A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site📍 Hangzhou Betta Pharmaceuticals Co., Ltd. · Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8… A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites📍 Birmingham📍 Duarte📍 Boston Taiho Oncology, Inc. · Tests: TAS6417, CYP Cocktail, Transporter Cocktail A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site📍 Jerusalem Hadassah Medical Organization · Tests: Stereotactic surgery A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites📍 Hefei📍 Harbin📍 Wuhan Abbisko Therapeutics Co, Ltd · Tests: ABSK043 in combination with Firmonertinib A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations NCT06514027Phase 21 site📍 Guangzhou BeBetter Med Inc · Tests: BEBT-109 Capsules, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site📍 Suzhou Allist Pharmaceuticals, Inc. · Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC NCT06109558Phase 1, Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: LMV-12(HE003) Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis NCT07348965NA1 site📍 Guangzhou Guangzhou University of Traditional Chinese Medicine · Tests: Furmonertinib 320mg qod po, Furmonertinib 160mg qd po Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer NCT05401110Phase 15 sites📍 Beverly Hills📍 Los Angeles📍 Los Angeles Karen Reckamp, MD, MS · Tests: Osimertinib, Carotuximab A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site📍 Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: Almonertinib, Placebo Almonertinib Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site📍 Guangzhou Avistone Biotechnology Co., Ltd. · Tests: PLB1004 Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations. NCT07392658Phase 21 site📍 Roma Fondazione Ricerca Traslazionale · Tests: Amivantamab Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA NCT05334277Phase 226 sites📍 Changchun📍 Chengdu📍 Dongguan Sun Yat-sen University · Tests: Furmonertinib, Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) NCT07079475Phase 1, Phase 214 sites📍 Beijing📍 Guangzhou📍 Harbin Dizal Pharmaceuticals · Tests: DZD6008, Sunvozertinib, Osimertinib Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC NCT05852990Phase 31 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Glutamine plus L. reuteri Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression NCT06269211Phase 22 sites📍 Guangzhou📍 Shanghai Ruijin Hospital · Tests: Toripalimab A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites📍 Springdale📍 Duarte📍 Irvine AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting NCT07230691n/a86 sites📍 Graz📍 Klagenfurt📍 Natters Janssen Research & Development, LLC Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer NCT07738172Phase 31 site📍 Taipei National Taiwan University Hospital · Tests: Primary Tumor Resection, Osimertinib CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease NCT05257967NA1 site📍 Vancouver British Columbia Cancer Agency · Tests: Lumbar puncture and Phlebotomy Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973Phase 31 site📍 Jinan Qianfoshan Hospital · Tests: almonertinib Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) NCT05559645NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: DZD9008, DZD9008 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) NCT05099172Phase 1, Phase 294 sites📍 Gilbert📍 Duarte📍 Atlanta Bayer · Tests: BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer NCT07416994Phase 32 sites📍 Shanghai📍 Hangzhou MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Docetaxel Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification NCT07322783Phase 21 site📍 Qingdao Qingdao Central Hospital · Tests: • Drug: Savolitinib • Drug: Osimertinib Mesylate Tablets
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy